Institutional shares held 273 Million
6.7K calls
48.7K puts
Total value of holdings $317M
$7K calls
$56K puts
Market Cap $91.2M
78,654,800 Shares Out.
Institutional ownership 347.71%
# of Institutions 144


Latest Institutional Activity in LAB

Top Purchases

Q1 2025
Oppenheimer & CO Inc Shares Held: 86.6K ($100K)
Q1 2025
Rhumbline Advisers Shares Held: 413K ($479K)
Q1 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 20.3K ($23.5K)
Q1 2025
Pallas Capital Advisors LLC Shares Held: 12.4K ($14.3K)
Q4 2024
Mirabella Financial Services LLP Shares Held: 3.13M ($3.63M)

Top Sells

Q1 2025
Sumitomo Mitsui Trust Holdings, Inc. Shares Held: 6.23M ($7.23M)
Q1 2025
Sg Americas Securities, LLC Shares Held: 96.9K ($112K)
Q1 2025
Rothschild Investment LLC Shares Held: 121 ($140)
Q1 2025
Farther Finance Advisors, LLC Shares Held: 5 ($5.8)
Q4 2024
Ark Investment Management LLC Shares Held: 3.32M ($3.86M)

About LAB

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.


Insider Transactions at LAB

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
20.1M Shares
From 16 Insiders
Grant, award, or other acquisition 3.88M shares
Other acquisition or disposition 1.75M shares
Open market or private purchase 14.2M shares
Exercise of conversion of derivative security 332K shares
Sell / Disposition
1.94M Shares
From 4 Insiders
Other acquisition or disposition 1.75M shares
Payment of exercise price or tax liability 198K shares

Track Institutional and Insider Activities on LAB

Follow STANDARD BIOTOOLS INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LAB shares.

Notify only if

Insider Trading

Get notified when an Standard Biotools Inc. insider buys or sells LAB shares.

Notify only if

News

Receive news related to STANDARD BIOTOOLS INC.

Track Activities on LAB